Beleodaq is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.<\/p>\n
BELEODAQ (belinostat) for injection, for intravenous administration Initial U.S. Approval: 2014
\nTo access belinostat for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Belinostat is is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).<\/p>\n
Disease Indications-Lymphoma If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cbelinostat for injection\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Spectrum Pharmaceuticals, Inc.
\nUsage-Intravenous
\nMedicine Approved By-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n